Search research articles
Contact Us
Filters
Showing results (61-70 of 67) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 67 results.
Oncogene
|
June 20, 2017
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer
J Jen, L-L Lin, F-Y Lo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2015
Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)
M De Santis, P J Wiechno, J Bellmunt, et al.
British Journal of Cancer
|
April 24, 2014
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
C-C Lin, W-C Su, C-J Yen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2018
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer
D E Gerber, L Horn, M Boyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2020
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
V A Papadimitrakopoulou, T S Mok, J-Y Han, et al.
ESMO Open
|
May 4, 2023
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
G Galffy, I Lugowska, E V Poddubskaya, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2024
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC
H A Yu, C Baik, D-W Kim, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 67) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 67 results.
Oncogene
|
June 20, 2017
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer
J Jen, L-L Lin, F-Y Lo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2015
Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)
M De Santis, P J Wiechno, J Bellmunt, et al.
British Journal of Cancer
|
April 24, 2014
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
C-C Lin, W-C Su, C-J Yen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2018
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer
D E Gerber, L Horn, M Boyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2020
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
V A Papadimitrakopoulou, T S Mok, J-Y Han, et al.
ESMO Open
|
May 4, 2023
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
G Galffy, I Lugowska, E V Poddubskaya, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2024
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC
H A Yu, C Baik, D-W Kim, et al.
Page
of 7